The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01757431 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Atypical Hemolytic Uremic Syndrome (aHUS)

Interventions

DRUG: Eculizumab

Sponsor

Alexion Pharmaceuticals, Inc.